Probiotics and antibiotics in IBD

Digestive Diseases

Volumn 32, Issue , 2014, Pages 10-17

  Sokol, Harry ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UMR1319 MICALIS   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Antibiotics; IBD; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; MESALAZINE; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DYSBIOSIS; HUMAN; ILEITIS; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MAINTENANCE THERAPY; NONHUMAN; RECURRENT DISEASE; RELAPSE; REMISSION; ULCERATIVE COLITIS; DRUG EFFECTS; GASTROINTESTINAL TRACT; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; MICROFLORA; PATHOLOGY;

ANTI-BACTERIAL AGENTS; CROHN DISEASE; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; MICROBIOTA; PROBIOTICS;

EID: 84919791578     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000367820     Document Type: Article

References (81)

1. Khor B, Gardet A, Xavier RJ: Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-317.
2. Jostins L, Ripke S, Weersma RK, et al: Hostmicrobe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
3. Manichanh C, Borruel N, Casellas F, et al: The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 599-608.
4. Sokol H, Lay C, Seksik P, et al: Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 2008; 14: 858-867.
5. Hugot JP, Chamaillard M, Zouali H, et al: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
6. D'Haens GR, Geboes K, Peeters M, et al: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267.
7. Rutgeerts P, Goboes K, Peeters M, et al: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-774.
8. Harper PH, Lee EC, Kettlewell MG, et al: Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279-284.
9. Elinav E, Strowig T, Kau AL, et al: NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745-757.
10. Garrett WS, Lord GM, Punit S, et al: Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007; 131: 33-45.
11. Darfeuille-Michaud A, Neut C, Barnich N, et al: Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115: 1405-1413.
12. Sokol H, Lepage P, Seksik P, et al: Temperature gradient gel electrophoresis of fecal 16s rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. J Clin Microbiol 2006; 44: 3172-3177.
13. Sokol H, Pigneur B, Watterlot L, et al: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
14. Khan KJ, Ullman TA, Ford AC, et al: Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-673.
15. Afdhal NH, Long A, Lennon J, et al: Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 1991; 36: 449-453.
16. Prantera C, Kohn A, Mangiarotti R, et al: Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-518.
17. Selby W, Pavli P, Crotty B, et al: Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-2319.
18. Campieri M, Rizzello F, Venturi A: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 2000; 118:A781.
19. Ohkusa T, Kato K, Terao S, et al: Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010; 105: 1820-1829.
20. Ohkusa T, Nomura T, Terai T, et al: Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005; 40: 1334-1342.
21. Oliva S, Di Nardo G, Ferrari F, et al: Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012; 35: 327-334.
22. Abdelrazeq AS, Kelly SM, Lund JN, et al: Rifaximin- ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005; 7: 182-186.
23. Gionchetti P, Rizzello F, Venturi A, et al: Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13: 713-718.
24. Mimura T, Rizzello F, Helwig U, et al: Fourweek open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16: 909-917.
25. Atarashi K, Tanoue T, Shima T, et al: Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2010; 331: 337-341.
26. Sarrabayrouse G, Bossard C, Chauvin JM, et al: CD4CD8αα lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. PLoS Biol 2014; 12: e1001833.
27. Arpaia N, Campbell C, Fan X, et al: Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-455.
28. Furusawa Y, Obata Y, Fukuda S, et al: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-450.
29. Steidler L, Hans W, Schotte L, et al: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352-1355.
30. Motta JP, Bermudez-Humaran LG, Deraison C, et al: Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012; 4: 158ra144.
31. Hanson ML, Hixon JA, Li W, et al: Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 2014; 146: 210-221.e213.
32. Graham D, Al-Assi M, Robbins M: Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology 1995; 108:A826.
33. Steinhart AH, Feagan BG, Wong CJ, et al: Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40.
34. Leiper K, Martin K, Ellis A, et al: Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 2008; 27: 1233-1239.
35. Sutherland L, Singleton J, Sessions J, et al: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075.
36. Arnold GL, Beaves MR, Pryjdun VO, et al: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15.
37. Prantera C, Lochs H, Campieri M, et al: Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo- controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23: 1117-1125.
38. Prantera C, Lochs H, Grimaldi M, et al: Rifaximin- extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481.e474.
39. Colombel JF, Lemann M, Cassagnou M, et al: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674-678.
40. Steed H, Macfarlane GT, Blackett KL, et al: Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883.
41. Malchow HA: Crohn's disease and Escherichia coli . A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653-658.
42. Guslandi M, Mezzi G, Sorghi M, et al: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-1464.
43. Bousvaros A, Guandalini S, Baldassano RN, et al: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11: 833-839.
44. Bourreille A, Cadiot G, Le Dreau G, et al: Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 2013; 11: 982-987.
45. Prantera C, Scribano ML, Falasco G, et al: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409.
46. Marteau P, Lemann M, Seksik P, et al: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006; 55: 842-847.
47. Van Gossum A, Dewit O, Louis E, et al: Multicenter randomized-controlled clinical trial of probiotics ( Lactobacillus johnsonii , LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 2007; 13: 135-142.
48. Elliott PR, Burnham WR, Berghouse LM, et al: Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 1982; 23: 132-134.
49. Shaffer JL, Hughes S, Linaker BD, et al: Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25: 203-205.
50. Basilisco G, Campanini M, Cesana B, et al: Risk factors for first operation in Crohn's disease. Am J Gastroenterol 1989; 84: 749-752.
51. Swift GL, Srivastava ED, Stone R, et al: Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994; 35: 363-368.
52. Goodgame RW, Kimball K, Akram S, et al: Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1861-1866.
53. Rutgeerts P, Hiele M, Geboes K, et al: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621.
54. Rutgeerts P, Van Assche G, Vermeire S, et al: Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861.
55. Manosa M, Cabre E, Bernal I, et al: Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial. Inflamm Bowel Dis 2013; 19: 1889-1895.
56. Herfarth HH, Katz JA, Hanauer SB, et al: Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2013; 19: 1073-1079.
57. Mantzaris GJ, Hatzis A, Kontogiannis P, et al: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-46.
58. Mantzaris GJ, Petraki K, Archavlis E, et al: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36: 971-974.
59. Mantzaris GJ, Archavlis E, Christoforidis P, et al: A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997; 92: 454-456.
60. Turunen UM, Farkkila MA, Hakala K, et al: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-1078.
61. Burke DA, Axon AT, Clayden SA, et al: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990; 4: 123-129.
62. Dickinson RJ, O'Connor HJ, Pinder I, et al: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-1384.
63. Lobo AJ, Burke DA, Sobala GM, et al: Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther 1993; 7: 155-158.
64. Kato K, Mizuno S, Umesaki Y, et al: Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141.
65. Ishikawa H, Akedo I, Umesaki Y, et al: Randomized controlled trial of the effect of bifidobacteria- fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63.
66. Tursi A, Brandimarte G, Papa A, et al: Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo- controlled study. Am J Gastroenterol 2010; 105: 2218-2227.
67. Matthes H, Krummenerl T, Giensch M, et al: Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010; 10: 13.
68. Sood A, Midha V, Makharia GK, et al: The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202-1209, 1209.e1.
69. Miele E, Pascarella F, Giannetti E, et al: Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443.
70. Kruis W, Schutz E, Fric P, et al: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858.
71. Rembacken BJ, Snelling AM, Hawkey PM, et al: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639.
72. Kruis W, Fric P, Pokrotnieks J, et al: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623.
73. Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-698.
74. Wildt S, Nordgaard I, Hansen U, et al: A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus LA-5 and Bifidobacterium animalis subsp. Lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011; 5: 115-121.
75. Shen B, Achkar JP, Lashner BA, et al: A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-305.
76. Sambuelli A, Boerr L, Negreira S, et al: Budesonide enema in pouchitis - a doubleblind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002; 16: 27-34.
77. Isaacs KL, Sandler RS, Abreu M, et al: Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007; 13: 1250-1255.
78. Madden MV, McIntyre AS, Nicholls RJ: Double- blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193-1196.
79. Gionchetti P, Rizzello F, Venturi A, et al: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a doubleblind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309.
80. Mimura T, Rizzello F, Helwig U, et al: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114.
81. Gionchetti P, Rizzello F, Helwig U, et al: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209.